Expert: Prepping Suppliers For Surprise Audits Imperative For Device Firms Under EU Unannounced Inspection Scheme
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers selling product in the European Union must work with critical suppliers to ensure they're audit-ready now that unannounced inspections by notified bodies are standard practice in the EU, an industry expert says. Specifically, it's important for vendors to have procedures in place that address surprise inspections, and device firms should warn suppliers to not turn away third-party auditors when they knock on their door. PLUS: A detailed Q&A-format table to aid manufacturers in understanding the European Union's new unannounced audit scheme.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.